Community Outreach News

The way to the community is through engaging trusted community leaders. LUNGevity regularly updates these leaders and key stakeholders on our health equity programs and accomplishments, as well as valuable resources, partnership announcements, and opportunities to engage. Sign up to stay in the know about the latest in LUNGevity’s health equity work.

January 18, 2022

September 23, 2021

July 7, 2021

January 27, 2021

December 1, 2020



LUNGevity submits publications to peer-reviewed journals to share learnings and help advance best practices.

Winkfield KM, Regnante JM, Miller-Sonet E, et al. Development of an actionable framework to address cancer care disparities in medically underserved populations in the United States: expert roundtable recommendations. JCO Oncol Pract. 2021 March; 17(3): e278-e293 doi: 10.1200/OP.20.00630. Epub 2021 Jan 19.

Regnante JM, Richie N, Fashoyin-Aje L, et al. Operational strategies in US cancer centers of excellence that support the successful accrual of racial and ethnic minorities in clinical trials. Contemp Clin Trials Commun. 2020 March; 17: ISSN 2451-8654. doi: 10.1016/j.con.ctc.2020.100532.

Regnante JM, Richie NA, Fashoyin-Aje L, et al. US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials. J Oncol Pract. 2019 Apr;15(4):e289-e299. doi: 10.1200/JOP.18.00638. Epub 2019 Mar 4.

Xie R, Dosreis S, Regnante JM, et al. Strategies to include underrepresented patient populations in patient-centered research. Abstract accepted, 2021 ISPOR Annual Meeting.

Regnante JM, Basu Roy U, O'Leary C, Fleisher LM, et al. Abstract PO-064: Health literacy as a tool to drive equitable action for lung cancer screening in high-risk communities. Cancer Epidemiol Biomarkers Prev. January 1 2022 (31) (1 suppl) PO-064; DOI: 10.1158/1538-7755.DISP21-PO-064.
Regnante JM, Fashoyin-Aje L, Miller Sonet E, et al. Abstract PO-084: The pharmaceutical industry in action: 2021 clinical research diversity and inclusion survey. Cancer Epidemiol Biomarkers Prev. January 1 2022 (31) (1 suppl) PO-084; DOI: 10.1158/1538-7755.DISP21-PO-084.
Fenske Williams E, Stober Murray M, Rollins V, et al. Abstract PO-105: Improving cancer care through inclusive clinical trials: An online collaborative community to improve representation in cancer clinical trials. Cancer Epidemiol Biomarkers Prev. January 1 2022 (31) (1 suppl) PO-105; DOI: 10.1158/1538-7755.DISP21-PO-105.